Cost-effectiveness analysis for multinational clinical trials

Statistics in Medicine

Volumn 24, Issue 13, 2005, Pages 1965-1982

  Pinto, Eleanor M ^a,b   Willan, Andrew R ^a,b   O'Brien, Bernie J ^c,d  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Programme for Appropriate Technology in Health Canada   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Cost effectiveness; Multinational clinical trials; Shrinkage estimators

Indexed keywords

ABCIXIMAB; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; TENECTEPLASE;

ACUTE HEART INFARCTION; ARTICLE; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG DOSE REGIMEN; HEALTH CARE POLICY; HEART CATHETERIZATION; HUMAN; INTERMETHOD COMPARISON; LENGTH OF STAY; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; MEDICAL DECISION MAKING; META ANALYSIS; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; SIMULATION; STATISTICAL ANALYSIS;

CLINICAL TRIALS; COST-BENEFIT ANALYSIS; HUMANS; INTERNATIONALITY; MYOCARDIAL INFARCTION; ONTARIO; THROMBOLYTIC THERAPY;

EID: 21244475080     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.2078     Document Type: Article

References (42)

1. O'Brien BJ, Drummond MF, Labelle RJ, Willan AR. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in heath care. Medical Care 1994; 32:150-163.
2. Mullahy J, Manning W. Statistical issues of cost-effectiveness analysis. In Valuing Health Care, Sloan F (ed.). Cambridge University Press: Cambridge, 1994; 149-184.
3. Wakker P, Klaassen MP. Confidence intervals for cost/effectiveness ratios. Health Economics 1995; 4:373-381.
4. Willan AR, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. Health Economics 1996; 5:297-305.
5. Chaudhary MA, Stearns SC. Confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Statistics in Medicine 1996; 15:1447-1458.
6. Mullahy J. What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation. Medical Care 1996; 34(12 Suppl.):DS124-DS135.
7. Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in cost effectiveness analysis. In Cost Effectiveness in Health and Medicine, Gold MR, Siegel JE, Russell LB, Weinstein MC (eds). Oxford University Press: New York, 1996.
8. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps; a non-parametric approach to confidence interval estimation. Health Economics 1997; 6:327-340.
9. Polsky D, Glick HA, Willke R, Schulman K. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Economics 1997; 6:243-252.
10. Willan AR, O'Brien BJ. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. Health Economics 1999; 8:203-211.
11. Phelps CE, Mushlin AI. On the (near) equivalence of cost-effectiveness and cost-benefit analysis. International Journal of Technology Assessment in Health Care 1991; 7:12-21.
12. Ament A, Baltussen R. The interpretation of results of economic evaluation: explicating the value of health. Health Economics 1997; 6:625-635.
13. Stinnett AA, Mallahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Medical Decision Making 1998; 18(Suppl.):S68-S80.
14. Tambour M, Zethraeus N, Johannesson M. A note on confidence intervals in cost-effectiveness analysis. International Journal of Technology Assessment 1998; 14:467-471.
15. van Hout BA, Al MJ, Gordon GS, Rutten FFH. Costs, effects and C/E ratios alongside a clinical trial. Health Economics 1994; 3:309-319.
16. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Economics 1998; 7:723-740.
17. Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. Health Economics 1999; 8:257-261.
18. Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Economics 2000; 9:623-630.
19. Heitjan DF. Fieller's method and net health benefit. Health Economics 2000; 9:327-335.
20. Willan AR. Analysis, sample size and power for estimating incremental net health benefit from clinical trial data. Controlled Clinical Trials 2001; 22:228-237.
21. Willan AR, Lin DY. Incremental net benefit in randomized clinical trials. Statistics in Medicine 2001; 20: 1563-1574.
22. Willan AR, Chen EB, Cook RJ, Lin DY. Incremental net benefit in clinical trials with quality-adjusted survival. Statistics in Medicine 2003; 22:353-362.
23. Willan AR, Lin DY, Cook RJ, Chen EB. Using inverse-weighting in cost-effectiveness analysis with censored data. Statistical Methods in Medical Research 2002; 11:539-551.
24. Cook JR, Drummond M, Glick H, Heyse JF. Assessing the appropriateness of combining economic data from multinational clinical trials. Statistics in Medicine 2003; 22:1955-1976.
25. Koopmanschap MA, Touw KCR, Rutten FFH. Analysis of cost and cost-effectiveness in multinational trials. Health Policy 2001; 58:175-186.
26. Wilke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Economics 1998; 7:481-493.
27. Manca A, Rice N, Sculpher MJ, Briggs AH. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Economics 2004 (www.interscience.wiley.com DOI: 10 1002/hec.914).
28. James W, Stein C. Estimation with quadratic loss. Proceedings of the Fourth Berkeley Symposium on Mathematical Statistics and Probability, vol. 1. University of California Press: Berkeley, 1961; 361-370.
29. Morris C. Interval estimation for empirical Bayes generalizations of Stein's estimator. Proceedings of the Twenty-Second Conference on the Design of Experiments in Arym Research Development and Testing, ARO Report 77-2, 1977.
30. Willan AR, Pinto EM, O'Brien BJ, Kaul P, Goeree R, Lynd L, Armstrong PW. Country-specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 Economic Analysis. Health Economics, (to appear).
31. Efron B, Morris C. Empirical Bayes on vector observations: an extension of Stein's method. Biometrika 1972; 59:335-347.
32. Morris C. Parametric empirical Bayes inference: theory and applications. Journal of the American Statistical Association 1983; 78:47-55.
33. Dersimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7:177-188.
34. The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-613.
35. Wallentin L, Lindahl B, Armstrong PW, Granger CB, Van de Werf F, ASSENT 3 Investigators. Influence of enoxaparin and early revascularization on death or myocardial infarction after thrombolysis in ST elevation myocardial infarction. European Heart Journal 2002; 23(Suppl.):639.
36. Ontario Case Cost Project. Ontario Case Cost Project (OCCP): Ontario Guide to Case Costing, Version 1.1. Ontario Case Cost Project: Ottawa, September, 1995.
37. Ontario Ministry of Health. Schedule of Benefits: Physician Services Under the Health Insurance Act, February 1, 1998. Queen's Printer: Toronto, Ontario, 1999.
38. Berger J. Comment on parameteric empirical Bayes inference: theory and applications. Journal of the American Statistical Association 1983; 78:55-57.
39. Rubin DB. Bayesianly justifiable and relevant frequency calculations for the applied statistician. The Annals of Statistics 1984; 12:1151-1172.
40. Thompson SG, Barber JA. How should cost data in pragmatic clinical trials be analysed? British Medical Journal 2000; 320:1197-1200.
41. Lumley T, Diehr P, Emerson S, Chen L. The importance of the normality assumption in large public health data sets. Annual Review of Public Health 2002; 23:151-169.
42. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Economics 2004; 13:461-475.